Company news
Onco-Innovations Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
Onco-Innovations and Redwood AI Secure Terry Fox Research Institute Grant to Advance AI-Powered SynoGraph(TM) Oncology Platform
September 22, 2026
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd.
September 10, 2026
Onco-Innovations Provides Interim Report on Microsome Studies Across Three Species
September 9, 2026
Onco-Innovations Announces Shares for Debt Settlement
September 8, 2026
Onco-Innovations Enters into LOI with Ifowonco for Exclusive Option and Worldwide Licence to LAG-3 Small-Molecule Inhibitor Program
August 19, 2026
Onco-Innovations Initiates ADME Studies Supporting Development of ONC010
July 16, 2026
Onco-Innovations Announces Entry into Loan Agreements
July 15, 2026
Onco-Innovations Completes Analytical Reference Standard Preparation Program for ONC010's API
July 10, 2026
Onco-Innovations Announces Term Sheet for Notional CAD$5 Million Performance-Based Funding Arrangement and Amendments to Previously Announced Financing
June 30, 2026
Onco-Innovations Initiates Polymer Process Development and Characterization Program for ONC010
June 30, 2026
Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
June 26, 2026
NetworkNewsAudio Announces Audio Press Release (APR) Discussing the Development of PNKP Inhibitors in Oncology Drug Development
June 26, 2026
Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Leading Out in Developing Fresh Wave of Inhibitor Classes
June 25, 2026
Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
June 24, 2026
Onco-Innovations Engages Nanosoft Polymers to Advance Polymer and Drug Delivery Development for ONC010
June 23, 2026
Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) Advancing Nanoparticle-Encapsulated PNKP Inhibitor in Oncology Space
June 23, 2026
Next-Generation DNA Repair Therapies Open New Frontiers in Oncology
June 22, 2026
Onco-Innovations Announces Non-Brokered LIFE Offering
June 19, 2026
Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
June 19, 2026
Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization
June 16, 2026
Onco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP Inhibitor Technology
June 9, 2026
Onco-Innovations Signs LOI with Nanosoft Polymers to Advance Polymer and Drug Delivery Development for the ONC010 Program
June 5, 2026
Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program
June 2, 2026
Onconetix, Inc. Announces 1-for-10 Reverse Stock Split
May 19, 2026
Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
May 15, 2026
Onco-Innovations Announces Initiation of Research Collaboration within PROmAI
May 12, 2026
Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation
May 5, 2026
Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies
May 1, 2026
Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program
April 28, 2026
Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies
April 23, 2026
Onco-Innovations Announces Completion of Analytical Method Development for Monomer Intermediate 1 Supporting ONC010 Program
April 21, 2026
Onco-Innovations Strengthens Executive Leadership with Appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development
April 17, 2026
Onco-Innovations Executes Engagement Agreement with RDI Partners and Establishes Onco-Innovations AU Pty. Ltd. to Advance Australian Phase I Strategy
April 7, 2026
OneMedNet, Onco-Innovations and Inka Health Announces Collaboration Aimed to Accelerate Potential for Oncology Drug Development Using Real-World Data and AI
April 1, 2026
Onconetix, Inc. Announces 1-for-5 Reverse Stock Split
March 23, 2026
Onco-Innovations Announces Closing of Private Placement
March 12, 2026
Realbotix Corp. Announces the Sale of Realbotix, LLC Subsidiary to a NASDAQ Listed Issuer
February 12, 2026
Onco-Innovations Announces Filing of Preliminary Base Shelf Prospectus
February 4, 2026
Onco-Innovations Announces Private Placement
January 23, 2026
Onco-Innovations Engages i2i Marketing Group Engagement for Market Awareness Services
January 21, 2026
Onco-Innovations Chairs Colorectal Cancer Canada Precision Oncology Forum Generating Roadmaps for the Next Era of Cancer Care
December 9, 2025
Onco-Innovations Engages Investment Bank to Pursue Nasdaq Cross-listing and Potential Concurrent Equity Offering
December 7, 2025
Onco-Innovations Attends University of Alberta's 2025 Innovation Awards
November 25, 2025
Onco-Innovations Advances Optimization and Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services to Support Future Phase 1 Clinical Studies
November 20, 2025
Onco-Innovations Advances AI and Quantum Drug Discovery with Kuano Collaboration to Accelerate PNKP Inhibitor Technology Development
November 18, 2025
Onco-Innovations' Inka Health Publishes Framework on Transportability of Real-World Evidence and Use in Health Technology Assessment
November 7, 2025
Onco-Innovations Provides Shareholder Update Following Cboe Canada Investor Spotlight
October 31, 2025
Onco-Innovations Appoints Jared Rushton to Board of Directors
October 30, 2025
Onco-Innovations Advances Preclinical Program as Nucro-Technics Begins Analytical Development for PNKP Technology
September 28, 2025
Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement
September 26, 2025
Decks
- Investor Presentation (March 2025)
Investor deck · 22 slides · March 2025
- Investor Presentation (February 2025)
Investor deck · 21 slides · February 2025